A Randomized Phase 3 Study to Evaluate Two Formulations of Romosozumab in Postmenopausal Women With Osteoporosis
Status:
Completed
Trial end date:
2014-12-08
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare 2 formulations of romosozumab (AMG 785) on bone
mineral density (BMD) in postmenopausal women with osteoporosis.